A federal appeals court just handed Gilead Sciences (GILD) a legal win that extends into the company’s revenue.
The decision blocks a group of companies from importing cheaper foreign versions of Gilead’s top HIV drug and selling them to American patients.
For a company that relies heavily on a single medicine, that protection matters a lot.
Gilead Sciences closed at $138.36on August 14, an increase of more than 13% since the start of 2026.
Read on to learn what the court decided, why it protects Gilead’s core business, and what investors should watch next.
What the appeals court decided in Gilead’s favor
The U.S. Court of Appeals for the Fourth Circuit upheld a preliminary injunction on Thursday, August 13.
That injunction stops several companies from importing Gilead’s HIV medications from overseas and selling them to U.S. patients through employer health plans, according to CNBC.
The companies involved run what are called alternative funding programs, or AFPs.
More Healthcare Stocks:
- Key HIV stat over 70% leaves BofA siding with Gilead
- BofA biotech scorecard: Two buys and odd one out
- Morgan Stanley uncovers major Bristol Myers stock signals
An AFP is a third-party vendor that employers hire to lower drug costs.
Many of them do this by buying medicines from other countries, where prices are often much lower than in the U.S.
The court ruled that the foreign version of the drug and the U.S. version were not the same product in any meaningful sense.
It called the differences material, not just technical, according to Bloomberg Law.
Why the imported HIV drug case started
The lawsuit traces back to one patient and a package.
Gilead sued in December 2024 after a Maryland patient received its HIV drug Biktarvy in the mail from Turkey, with the label instructions printed in Turkish, CNBC noted.
The company named an AFP called Rx Valet and several affiliated firms in the suit.
The lawsuit also named two other companies. One was Meritain Health, a unit of CVS Health-owned Aetna that manages employee health plans. The other was Pro-Act, a pharmacy benefit manager.
The court sided with Gilead on two legal claims: trademark infringement and unfair competition.
Its reasoning came down to one point. The imported Biktarvy passed through a different quality-control system than the U.S. version, so the two products were not the same in any way that counted.
That single finding is why the injunction held up on appeal.
How the ruling protects Gilead’s U.S. pricing
This is the part that actually affects Gilead’s sales.
AFPs work like this: an employer’s health plan buys Biktarvy from another country, where it costs less, then mails it to the patient in the U.S.
The patient never pays the higher American price, and neither does the health plan.
The ruling stops the named companies from doing that. Now those employers and insurers have to buy Biktarvy the normal way, at full U.S. prices, from Gilead directly.
Related: JPMorgan resets LLY stock target on drug demand
Patient advocacy groups say this could shrink the AFP industry significantly. Some AFPs may have to shut down entirely.
For Gilead, that’s good news. Fewer cheap imports competing with Biktarvy means the price Gilead charges for its biggest drug stays where it is.
Why Biktarvy is the number that matters
- Biktarvy generated about $14.3 billion in full-year 2025 sales, making it Gilead’s single largest product.
- Second-quarter 2026 Biktarvy sales reached $3.8 billion, up 7% from a year earlier.
- HIV drugs accounted for roughly 70% of Gilead’s $29.4 billion in 2025 revenue, according to a press release.
When one drug carries that much of the business, a threat to its price is a threat to the whole company.
What the ruling means for Gilead’s revenue outlook
Gilead’s second quarter backs up the timing.
HIV sales hit $5.7 billion, up 12% from a year earlier. Biktarvy and Gilead’s HIV prevention drugs drove that growth.
Base business sales rose 10% to $7.6 billion. That number excludes the Covid treatment Veklury. It’s also the fastest second-quarter growth Gilead has posted in three years.
The company’s management raised its full-year sales outlook because of that strength. The new range is $29.8 billion to $30.1 billion, up from $29.4 billion to $29.8 billion.
The company also raised its HIV sales growth forecast for the year, from 8% to a range of 9% to 10%.
That guidance assumes U.S. patients keep paying domestic prices for Biktarvy. Blocking cheaper foreign imports helps make sure that assumption holds.
The second legal win that removed another risk
This ruling is not the only courtroom result going Gilead’s way this month.
On August 3, the California Supreme Court ruled 6-1 in Gilead’s favor in a separate case, rejecting a legal theory known as a “duty to innovate,” STAT reported.
That case was brought by an estimated 24,000 patients who took an older Gilead HIV drug made with tenofovir disoproxil fumarate.
The plaintiffs argued Gilead was negligent for delaying a safer alternative, even though they did not claim the original drug was defective.
The court disagreed, and ordered the claims dismissed.
Two wins in the same month remove two separate risks that had hung over the stock, one on pricing and one on liability.
What Wall Street thinks about Gilead now
Analysts were already positive before these rulings.
Gilead carries a consensus StrongBuy rating, with an average 12-month price target of about $158.
Bank of America is more bullish than the average, keeping a Buy rating and a $162 price target after the second-quarter report.
With the stock near $138, both figures imply the stock still has room to grow above the current price.
The court rulings do not change those targets on their own, but they take two risks off the table that could have pulled estimates lower.
How Gilead stock has performed against the market
This year, Gilead’s stock has moved almost in step with the broader market.
GILD share-price snapshot
- Closed at $138.36 on August 14, up 4.51% over the prior five trading days.
- Up more than 13% since January 2, 2026, roughly in line with the S&P 500‘s gain over the same stretch.
- 52-week range of $108.46 to $157.27, leaving the stock about 12% below its high.
- Market value of about $171.56 billion, with a dividend yield near 2.37%.
The gap between the current price and the 52-week high shows how much ground the stock could recover if the coming drug launches land on schedule.
The catalysts Gilead investors should track next
Two FDA decisions are coming up soon.
The first is due August 27. It covers a new daily pill that combines two of Gilead’s HIV drugs, bictegravir and lenacapavir, into one regimen.
It’s meant for patients whose HIV is already under control and who want to switch to a single pill.
The second decision is due December 23. It covers anito-cel, a cell therapy for a hard-to-treat form of multiple myeloma, a type of blood cancer.
Beyond those two, Gilead is also working on a once-weekly HIV treatment with Merck. That drug combines islatravir and lenacapavir, and Gilead hopes to launch it in 2027.
If these drugs get approved, each one gives Gilead a new source of revenue. But FDA reviews don’t always go as planned. Decisions can be delayed, and approval is never certain.
What this means for investors weighing GILD now
Gilead is a company built on one dominant franchise, and both August rulings defend that franchise directly.
The appeals court decision protects U.S. Biktarvy pricing from cheaper foreign imports, and the California ruling clears a large liability claim tied to older HIV drugs.
The main risk now is execution, not legal exposure.
Gilead’s reported second-quarter profit already took an $11.2 billion hit from research charges tied to recent acquisitions.
Those charges are one-time, but they show how much the company is spending to build its next wave of growth.
The two rulings remove two specific risks. They do not guarantee the stock goes up.
Gilead still needs its upcoming drug approvals to go well.
Watch the FDA decision on August 27 and the one on December 23. Both need to land on time for the bullish case to hold up.
Anyone considering the stock should size the position to their own risk tolerance. The number to watch closely is how well Gilead’s HIV franchise holds its pricing power in the U.S.
This is not investment advice, and drug-approval timelines can shift in either direction before year-end.
